Agilera Pharma AS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Agilera Pharma AS - overview
Established
2023
Location
-, -, Norway
Primary Industry
Pharmaceuticals
About
Agilera Pharma AS, based in Norway, operates as a Contract Development and Manufacturing Organization (CDMO) specializing in radio-pharmaceuticals, focusing on comprehensive services from development to distribution. Founded in 2023 in Norway, Agilera Pharma AS functions within the radio-pharmaceutical sector, offering development and manufacturing services. In June 2025, PharmaLogic Holdings LLC agreed to acquire a majority stake in Agilera Pharma AS from Institute for Energy Technology. Erik Flatmark is leading the firm as CEO as of 2025.
Agilera specializes as a Contract Development and Manufacturing Organization (CDMO) in the radio-pharmaceutical sector, providing a comprehensive suite of services that spans the entire product development lifecycle. Their core offerings include the development of new radio-pharmaceuticals, from the preclinical phase through to commercial production and global distribution. The company aims to address significant medical needs by facilitating access to advanced cancer therapies, thereby improving patient outcomes. Agilera serves a diverse client base that includes pharmaceutical companies, research institutions, and healthcare providers across various regions such as the United States, Japan, Europe, Latin America, and China.
This extensive geographical reach underscores Agilera's commitment to ensuring that innovative radio-pharmaceuticals are delivered to patients worldwide. Agilera's revenue model is constructed around providing tailored, comprehensive services to clients in the pharmaceutical industry. Transactions typically occur through strategic partnerships and contractual agreements wherein clients engage Agilera for the development and manufacturing of radio-pharmaceuticals. These agreements are designed to provide clients with seamless access to the company's expertise and capabilities throughout the product development process.
Pricing structures are generally based on the specific services rendered, which can include development fees, manufacturing costs, and distribution logistics, tailored to meet the needs of each client. As a result, Agilera maintains a diverse revenue stream that is reflective of its integral role within the pharmaceutical supply chain.
Current Investors
PharmaLogic Holdings LLC,
Primary Industry
Pharmaceuticals
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Specialty Pharmaceuticals
Website
www.agilera.no/
Total Amount Raised
Subscriber access only
Agilera Pharma AS - financials
| Fiscal Year Ended | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|
| Revenue (USD) | - | - | - |
| % Revenue Growth (YoY) | - | - | - |
| EBITDA (USD) | - | - | - |
| Operating Income (USD) | - | - | - |
| Operating Margin | - | - | - |
| % EBITDA Margin | - | - | - |
| NET Income (USD) | - | - | - |
| % Net Margin | - | - | - |
Agilera Pharma AS - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Carve Out | Completed | Agilera Pharma AS | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.